VERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360. These trials aimed to evaluate its efficacy, safety,... These trials aimed to evaluate its efficacy, safety, and tolerability in conditions such as SARS-CoV-2 infection, metastatic castration-resistant prostate cancer (mCRPC), respiratory distress syndrome in adults, and metastatic triple-negative breast cancer.
- Mechanism
- Curator reviewed
Veru-111 is a selective tubulin inhibitor currently being tested for the treatment of pancreatic cancer. Veru-111 represses alpha- and beta-tublin subunits through enhanced expression of miR-200C. In both melanoma and prostate cancer cell lines, it has displayed strong antiproliferative activity. It also prevents microtubule polymerization and causes cell cycle arrest in the G2/M phase, which suggests anti-tumor properties.
- Formula / weight
- C21H19N3O4 · 377.4 g/mol (avg)
- Also known as
- [2-(1H-indol-3-yl)-1H-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone · Methanone, [2-(1H-indol-3-yl)-1H-imidazol-5-yl](3,4,5-trimethoxyphenyl)- · Sabizabulin
- Code names
- ABI-231 · APP-111 · Veru-111
Resolves to
WQGVHOVEXMOLOK-UHFFFAOYSA-NSMILESCOC1=CC(=CC(OC)=C1OC)C(=O)C1=CNC(=N1)C1=CNC2=C1C=CC=C2What you can answer from here — as of July 08, 2026
Which companies are running trials of Veru-111, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account